Barclays
OKUR

Barclays’s OnKure Therapeutics OKUR Stock Holding History

Barclays’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$145K Buy
31,720
+6,720
+27% +$28.8K ﹤0.01% 3883
2026
Q1 		$104K Sell
25,000
-2,242
-8% -$6.92K ﹤0.01% 4008
2025
Q4 		$79K Buy
27,242
+26,621
+4,287% +$79.7K ﹤0.01% 4643
2025
Q3 		$1.71K Sell
621
-375
-38% -$929 ﹤0.01% 5154
2025
Q2 		$2.38K Sell
996
-5,769
-85% -$15.1K ﹤0.01% 5027
2025
Q1 		$29.1K Sell
6,765
-1,976
-23% -$11.1K ﹤0.01% 4729
2024
Q4 		$75.2K Buy
8,741
+8,718
+37,904% +$132K ﹤0.01% 4655
2024
Q3 		$389 Buy
23
+18
+360% +$266 ﹤0.01% 5155
2024
Q2 		$70 Sell
5
-811
-99% -$13.7K ﹤0.01% 4763
2024
Q1 		$13.5K Sell
816
-1,628
-67% -$26.9K ﹤0.01% 4786
2023
Q4 		$39.1K Sell
2,444
-5,368
-69% -$335K ﹤0.01% 4810
2023
Q3 		$595K Buy
7,812
+425
+6% +$28.9K ﹤0.01% 2684
2023
Q2 		$485K Buy
7,387
+194
+3% +$15.6K ﹤0.01% 2773
2023
Q1 		$430K Hold
7,193
– – ﹤0.01% 3370
2022
Q4 		$168K Hold
7,193
– – ﹤0.01% 3945
2022
Q3 		$241K Buy
7,193
+1,798
+33% +$59K ﹤0.01% 3100
2022
Q2 		$143K Buy
5,395
+5,039
+1,415% +$117K ﹤0.01% 3602
2022
Q1 		$10K Buy
+356
New +$19.9K ﹤0.01% 4606

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's OKUR Position: Q2 2026 in Review

Barclays increased its OnKure Therapeutics (OKUR) stake by 27% in Q2 2026, buying an estimated $28.8K and bringing the position to 31,720 shares worth $145K. The position accounts for ﹤0.01% of the portfolio, ranked #3883.

Barclays first reported a position in OKUR in Q1 2022 and has held it in 18 quarters since. The position peaked at $595K in Q3 2023. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Barclays held 31,720 shares of OnKure Therapeutics worth $145K as of Q2 2026.
  • Barclays bought 6,720 OnKure Therapeutics shares in Q2 2026, an estimated $28.8K.
  • OnKure Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3883 holding.
  • Barclays first reported a position in OnKure Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's OnKure Therapeutics position peaked at $595K in Q3 2023.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.